Sort
82,697 grants matching “vaccine development”
Novel Therapy for Pulmonary Anthrax
$1,000,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2011 · AI
University of New Mexico Cancer Center Support Grant
$1,000,000Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2020 · CA
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2015 · AI
HIV-1/SIV Antibody Neutralization Assay Improvements and Database Development
$1,000,000Christos J Petropoulos · Monogram Biosciences, Inc. · R44 · FY2007 · AI
HIV pathogenesis, prevention and treatment in the Andes
$1,000,000Asociacion Civil Impacta Salud Y Educacn · U19 · FY2004 · AI
Pre-IND Development of an Arenavirus Antiviral
$1,000,000Gregory William Henkel · Arisan Therapeutics, Inc. · R44 · FY2020 · AI
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
$1,000,000Sumana Chakravarty · Sanaria, Inc. · U44 · FY2025 · AI
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$1,000,000Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2021 · AI
Intranasal Vaccine Against Lyme Disease
$1,000,000Maria Gomes-Solecki · Immuno Technologies, Inc. · R44 · FY2023 · AI
Chemical Stabilization of shRNAs and their development as hepatitis C drugs
$1,000,000Brian H. Johnston · Somagenics, Inc. · R44 · FY2011 · AI
Automating mosquito microdissection for a malaria PfSPZ vaccine
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2021 · AI
Development of VLP vaccine for RSV
$1,000,000Jorge C Blanco · Sigmovir Biosystems, Inc. · R44 · FY2020 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2023 · AI
Novel immunotherapy against MOG antibody disease
$1,000,000Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2024 · TR
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)
$1,000,000Xiaowu Pang · Tengen Biomedical Co. · R42 · FY2023 · AI
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
$1,000,000Emmanuel B Walter · Duke University · U01 · FY2023 · IP
Pre-Clinical HPV16 Antiviral Compound Development
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2008 · AI
The Southwest National Primate Research Center
$1,000,000Kenneth Parkhurst Trevett · Texas Biomedical Research Institute · P51 · FY2010 · RR
A Vaccine for Lymphatic Filariasis, LFGuardâ¢
$1,000,000Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2022 · AI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
$1,000,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2023 · AI
Novel Therapy for Pulmonary Anthrax
$1,000,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2010 · AI
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2025 · AI
In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2020 · AI
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2020 · AI